Montelukast Ameliorates 2K1C-Hypertension Induced Endothelial Dysfunction and Associated Vascular Dementia.

IF 1.5 Q3 PERIPHERAL VASCULAR DISEASE

Current Hypertension Reviews Pub Date : 2024-01-01 DOI:10.2174/0115734021276985231204092425

Surbhi Gupta, Prabhat Singh, Bhupesh Sharma

{"title":"Montelukast Ameliorates 2K1C-Hypertension Induced Endothelial Dysfunction and Associated Vascular Dementia.","authors":"Surbhi Gupta, Prabhat Singh, Bhupesh Sharma","doi":"10.2174/0115734021276985231204092425","DOIUrl":null,"url":null,"abstract":"Background: Declined kidney function associated with hypertension is a danger for cognitive deficits, dementia, and brain injury. Cognitive decline and vascular dementia (VaD) are serious public health concerns, which highlights the urgent need for study on the risk factors for cognitive decline. Cysteinyl leukotriene (CysLT1) receptors are concerned with regulating cognition, motivation, inflammatory processes, and neurogenesis.Objective: This research aims to examine the consequence of montelukast (specific CysLT1 antagonist) in renovascular hypertension 2-kidney-1-clip-2K1C model-triggered VaD in experimental animals.Methods: 2K1C tactics were made to prompt renovascular hypertension in mature male rats. Morris water maze was employed to measure cognition. Mean arterial pressure (MAP), serum nitrite levels, aortic superoxide content, vascular endothelial activity, brain's oxidative stress (diminished glutathione, raised lipid peroxides), inflammatory markers (IL-10, IL-6, TNF-α), cholinergic activity (raised acetylcholinesterase), and cerebral injury (staining of 2, 3, 5- triphenylterazolium chloride) were also examined.Results: Montelukast in doses of 5.0 and 10.0 mg kg-1 was used intraperitoneally as the treatment drug. Along with cognitive deficits, 2K1C-operated rats showed elevated MAP, endothelial dysfunction, brain oxidative stress, inflammation, and cerebral damage with diminished serum nitrite/nitrate. Montelukast therapy significantly and dose-dependently mitigated the 2K1Chypertension- provoked impaired behaviors, biochemistry, endothelial functions, and cerebral infarction.Conclusion: The 2K1C tactic caused renovascular hypertension and associated VaD, which was mitigated via targeted regulation of CysLT1 receptors by montelukast administration. Therefore, montelukast may be taken into consideration for the evaluation of its complete potential in renovascular-hypertension-induced VaD.","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hypertension Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115734021276985231204092425","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Declined kidney function associated with hypertension is a danger for cognitive deficits, dementia, and brain injury. Cognitive decline and vascular dementia (VaD) are serious public health concerns, which highlights the urgent need for study on the risk factors for cognitive decline. Cysteinyl leukotriene (CysLT₁) receptors are concerned with regulating cognition, motivation, inflammatory processes, and neurogenesis.

Objective: This research aims to examine the consequence of montelukast (specific CysLT₁ antagonist) in renovascular hypertension 2-kidney-1-clip-2K1C model-triggered VaD in experimental animals.

Methods: 2K1C tactics were made to prompt renovascular hypertension in mature male rats. Morris water maze was employed to measure cognition. Mean arterial pressure (MAP), serum nitrite levels, aortic superoxide content, vascular endothelial activity, brain's oxidative stress (diminished glutathione, raised lipid peroxides), inflammatory markers (IL-10, IL-6, TNF-α), cholinergic activity (raised acetylcholinesterase), and cerebral injury (staining of 2, 3, 5- triphenylterazolium chloride) were also examined.

Results: Montelukast in doses of 5.0 and 10.0 mg kg^-1 was used intraperitoneally as the treatment drug. Along with cognitive deficits, 2K1C-operated rats showed elevated MAP, endothelial dysfunction, brain oxidative stress, inflammation, and cerebral damage with diminished serum nitrite/nitrate. Montelukast therapy significantly and dose-dependently mitigated the 2K1Chypertension- provoked impaired behaviors, biochemistry, endothelial functions, and cerebral infarction.

Conclusion: The 2K1C tactic caused renovascular hypertension and associated VaD, which was mitigated via targeted regulation of CysLT₁ receptors by montelukast administration. Therefore, montelukast may be taken into consideration for the evaluation of its complete potential in renovascular-hypertension-induced VaD.

查看原文本刊更多论文

孟鲁司特能改善 2K1C 高血压诱导的内皮功能障碍及相关血管痴呆症

背景：与高血压相关的肾功能衰退是认知障碍、痴呆和脑损伤的危险因素。认知功能衰退和血管性痴呆（VaD）是严重的公共卫生问题，因此迫切需要对认知功能衰退的风险因素进行研究。胱氨酰白三烯（CysLT1）受体涉及认知、动机、炎症过程和神经发生的调节：本研究旨在探讨孟鲁司特（特异性 CysLT1 拮抗剂）在翻新血管性高血压 2-Kidney-1-clip-2K1C 模型诱发的 VaD 实验动物中的作用。采用莫里斯水迷宫测量认知能力。同时还检测了平均动脉压（MAP）、血清亚硝酸盐水平、主动脉超氧化物含量、血管内皮活性、脑氧化应激（谷胱甘肽减少、脂质过氧化物升高）、炎症指标（IL-10、IL-6、TNF-α）、胆碱能活性（乙酰胆碱酯酶升高）和脑损伤（2，3，5-三苯基氯化三氮唑染色）：腹腔注射 5.0 和 10.0 毫克/千克剂量的孟鲁司特作为治疗药物。除认知障碍外，2K1C 手术大鼠还表现出血压升高、内皮功能障碍、脑氧化应激、炎症和脑损伤，血清亚硝酸盐/硝酸盐减少。孟鲁司特治疗可明显减轻2K1C高血压引起的行为、生化、内皮功能受损和脑梗塞，且剂量依赖性强：结论：2K1C 战术会引起新血管性高血压和相关的 VaD，而通过服用孟鲁司特可以靶向调节 CysLT1 受体，从而缓解这种情况。因此，可以考虑评估孟鲁司特在新血管性高血压诱发的 VaD 中的全面潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Hypertension Reviews PERIPHERAL VASCULAR DISEASE-

CiteScore

4.80

自引率

0.00%

发文量

期刊介绍： Current Hypertension Reviews publishes frontier reviews/ mini-reviews, original research articles and guest edited thematic issues on all the latest advances on hypertension and its related areas e.g. nephrology, clinical care, and therapy. The journal’s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all clinicians and researchers in the field of hypertension.